New Product, Patient Growth Key To ResMed

Australia | May 03 2021

Over the short term ResMed could find it difficult to surmount obstacles created by the pandemic while there is general agreement on an eventual return to growth

-Turnaround in new patient diagnoses critical to outlook
-AirSense 11 could trigger a resupply cycle in FY22
-Stronger medium-term growth expected


By Eva Brocklehurst

The commencement of the coronavirus pandemic a year ago significantly boosted ventilator sales and ResMed ((RMD)) is now cycling the impact. There were around $35m in ventilator sales that did not occur in the March quarter this year and there were lower new patient numbers in most markets.

Mask and accessory sales were up 4%, supported by US mask growth of 7%, while devices contracted -10%. Most of the latter drag came from outside the US, which was down just -2%, and stemmed from the second and third waves of the pandemic.

Moreover, gross margins declined, affected by elevated freight costs and the move to a new manufacturing site in Singapore. The company has also indicated that in the US, new patient diagnosis is around -10-20% lower than usual for a March quarter.

Goldman Sachs believes evidence this shortfall is narrowing is the critical factor that will drive a sustained performance of the company shares, while assuming trends continue to improve through the northern summer as vaccines are rolled out further.

On the other hand, the broker suspects the shortfall in mask growth may now be symptomatic of a cumulative deficit in diagnoses throughout the past 12 months. Therefore it may be some time before this returns to the quarterly average growth of 14% the market has become accustomed to see.

Revenue is expected to grow as hospitals gradually return to normal levels, although the company acknowledges growth in the first half of FY22 will be unlikely to rebound strongly because of a continuation of the pandemic outside of the US.

Long-Term Outlook

Over the longer term Goldman Sachs is positive about ResMed as it is a leader in an attractive market and the pricing outlook is the best in years. The broker, not one of the seven stockbrokers monitored daily on the FNArena database, has a Neutral rating and $28.40 target.

Macquarie also anticipates the recovery in new patient growth is likely to be gradual yet considers ResMed leveraged to improved activity. The balance sheet is favourable and this provides flexibility for capital management and/or growth initiatives. Still, with the stock trading at 35.2x on revised FY22 estimates Macquarie sticks with a Neutral rating.

Citi downgrades to Neutral from Buy while acknowledging the company is performing well in a difficult environment, while Wilsons, also not one of the seven, downgrades to Market Weight, with a target of $28.50.

Although the core sleep business is strong and there are plans for new products, Wilsons believes the "connected care" strategy, intended to drive device growth in conjunction with software solutions, has become contentious again.

The broker contends the devices industry is weak following the pandemic and lacks clarity now that oxygen has been discontinued for high-flow cannula use and, in remodelling flow generator sales, downgrades estimates for the short term.

Several obstacles prevented growth occurring in the quarter including seasonality, tough comparables and negligible ventilator sales for covid-19 use, yet Morgans assesses the headwinds are more cyclical than structural and an upgrade cycle is imminent as management has signalled the new AirSense 11 will be commercialised by the end of 2021.

AirSense 11

A limited launch of AirSense 11 has commenced in some states of the US and a broader commercial launch is expected later in this year. The company advises the launch in the US will be widespread by the end of 2021 and staggered subsequently to other countries.

Ord Minnett suspects customers may postpone orders ahead of the launch and this could weigh on sales in the short term but anticipates stronger growth in FY23 and beyond. The company could also benefit from Philips' inability to supply many markets, pending the approval of its new device outside the US. This leads the broker to upgrade to Hold from Lighten.

Given the success of the AirSense 10 largely stemmed from the cost advantage it offered distributors, Ord Minnett is optimistic the new device will support market share gains and higher margins as volumes ramp up.

The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE

If you already had your free trial, why not join as a paying subscriber? CLICK HERE